TFF Pharmaceuticals Inc. (TFFP) stock has faced a harrowing descent, touching a 52-week low of $0.21, a stark contrast to its performance over the past year. With a market capitalization of just $1.34 million and an InvestingPro Financial Health Score of 1.57 (rated as WEAK), the company's current struggles are evident. This significant downturn reflects a staggering 1-year change of -96.35%, underscoring the challenges the company has encountered in the market. Investors are closely monitoring TFFP as it navigates through this period of volatility, with the hope for potential recovery or strategic shifts that might reverse the current downward trend. InvestingPro analysis reveals the stock is currently in oversold territory, with 14 additional ProTips available to subscribers for deeper insight into TFFP's financial position.
In other recent news, TFF Pharmaceuticals is set to be delisted from Nasdaq, as per a recent filing with the U.S. Securities and Exchange Commission. The company has also announced significant advancements in its drug delivery methods and clinical trials. Roth/MKM maintained its Buy rating on the company, emphasizing the potential of its Thin Film Freezing technology in formulating dry powders for inhalation drug delivery.
TFF Pharmaceuticals has also formed a partnership with Emory University and the Biomedical Advanced Research and Development Authority. This collaboration aims to convert an mRNA-based Cas13a antiviral into a dry powder form for inhalation, potentially enhancing the distribution of therapies for respiratory viruses.
The company reported positive preclinical results for its universal influenza vaccine candidates, developed in collaboration with the Cleveland Clinic. Positive preliminary results have also been observed in TFF Pharmaceuticals' ongoing Phase 2 clinical trial of Tacrolimus Inhalation Powder for lung transplant rejection prevention. In a separate development, the company announced the resignation of Michael Patane from its Board of Directors. These are recent developments that continue to shape the future of TFF Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.